Apremilast (Otezla®)

Assessment Status NCPE Assessment Process Complete
Drug Apremilast
Brand Otezla®
Indication Alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
Assessment Process
Rapid review commissioned 24/02/2015
Rapid review completed 03/04/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 01/09/2015
NCPE assessment completed 29/04/2016
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.